We are live on ! Find out more
NXTM

NxStage Medical Inc.
NXTM

Delisted

NXTM was delisted on the 21st of February, 2019.

168 hedge funds and large institutions have $1.61B invested in NxStage Medical Inc. in 2017 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 39 increasing their positions, 51 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,040% more call options, than puts

Call options by funds: $28.2M | Put options by funds: $2.47M

11% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 55

3% more funds holding

Funds holding: 163168 (+5)

4% more capital invested

Capital invested by funds: $1.55B → $1.61B (+$66.3M)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

24% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 51

Holders
168
Holders Change
+5
Holders Change %
+3.07%
% of All Funds
4.19%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
61
Increased
39
Reduced
51
Closed
55
Calls
$28.2M
Puts
$2.47M
Net Calls
+$25.7M
Net Calls Change
+$23.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$148M +$4.16M +155,963 +3%
BlackRock
2
BlackRock
New York
$118M +$3.02M +113,060 +3%
AAM
3
Alpine Associates Management
Florida
$110M +$106M +3,991,458 New
MF
4
Magnetar Financial
Illinois
$84.9M +$82.1M +3,077,070 New
AA
5
AQR Arbitrage
Connecticut
$81.1M +$78.4M +2,939,902 New
Invesco
6
Invesco
Georgia
$66.3M -$1.43M -53,471 -2%
Deutsche Bank
7
Deutsche Bank
Germany
$62.2M +$57.7M +2,165,382 +2,445%
JP Morgan Chase
8
JP Morgan Chase
New York
$51.5M +$49.9M +1,869,961 +239,739%
PCM
9
Pennant Capital Management
New Jersey
$44.8M -$6.21M -233,000 -13%
DM
10
Deerfield Management
New York
$43.6M -$60.1M -2,254,045 -59%
GGHC
11
Gilder Gagnon Howe & Co
New York
$43.5M -$16.6M -623,920 -28%
State Street
12
State Street
Massachusetts
$36.8M -$189K -7,081 -0.5%
Goldman Sachs
13
Goldman Sachs
New York
$35.1M +$31.3M +1,173,012 +1,168%
PA
14
Perceptive Advisors
New York
$34.9M -$7.76M -291,000 -19%
CAM
15
Cortina Asset Management
Wisconsin
$30.7M +$1.5M +56,303 +5%
Grantham, Mayo, Van Otterloo & Co (GMO)
16
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$28.5M +$27.5M +1,032,500 New
Citigroup
17
Citigroup
New York
$24.8M +$23.9M +897,505 +209,209%
O
18
OppenheimerFunds
New York
$24.2M -$43.7K -1,637 -0.2%
Northern Trust
19
Northern Trust
Illinois
$24.2M -$107K -4,010 -0.5%
WIC
20
Water Island Capital
New York
$23.5M +$22.8M +853,218 New
OAM
21
Oxford Asset Management
United Kingdom
$22M +$19.5M +732,905 +1,136%
Norges Bank
22
Norges Bank
Norway
$21M +$9.93M +372,456 +96%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$19.5M +$2.45M +91,924 +15%
CFIC
24
City Financial Investment Company
United Kingdom
$19.3M +$18.7M +699,500 New
Wells Fargo
25
Wells Fargo
California
$19.2M -$628K -23,553 -3%

NXTM Hedge Fund Activity: Q3 2017 in Review

168 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in NxStage Medical Inc. (NXTM) for Q3 2017, worth a combined $1.61B — up 4.3% from $1.55B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new NXTM positions and 55 closed out — a net gain of 6 holders — while 39 added to existing stakes and 51 trimmed.

The largest buyer was Alpine Associates Management, opening a new position worth an estimated $106M. The largest seller was Fidelity Investments, cutting an estimated $249M.

  • 168 institutional investors held NxStage Medical Inc. (NXTM) as of Q3 2017, up from 163 in Q2 2017.
  • Funds reported $1.61B of NxStage Medical Inc. stock for Q3 2017, up 4.3% quarter-over-quarter.
  • 61 funds opened new NxStage Medical Inc. positions in Q3 2017 and 55 closed out, a net change of +6 holders.
  • The largest NxStage Medical Inc. buyer in Q3 2017 was Alpine Associates Management, an estimated $106M added.
  • The largest NxStage Medical Inc. seller in Q3 2017 was Fidelity Investments, an estimated $249M sold.

Based on aggregated 13F filings for Q3 2017.